These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36773046)

  • 21. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
    Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A descriptive study of Parkinson disease and atypical parkinsonisms in the Annuals of the Pathological Autopsy Cases in Japan.
    Horimoto Y; Sato C; Anan C; Suzuki A; Inagaki A; Tajima T; Hibino H; Inagaki H
    Neuropathology; 2023 Aug; 43(4):297-305. PubMed ID: 36336970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders.
    Constantinescu R; Rosengren L; Johnels B; Zetterberg H; Holmberg B
    Parkinsonism Relat Disord; 2010 Feb; 16(2):142-5. PubMed ID: 19647470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging.
    Cosottini M; Ceravolo R; Faggioni L; Lazzarotti G; Michelassi MC; Bonuccelli U; Murri L; Bartolozzi C
    Acta Neurol Scand; 2007 Jul; 116(1):37-42. PubMed ID: 17587253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of gray matter atrophy in atypical parkinsonism syndromes: a VBM meta-analysis.
    Yu F; Barron DS; Tantiwongkosi B; Fox P
    Brain Behav; 2015 Jun; 5(6):e00329. PubMed ID: 26085961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson's disease: evaluation by 3.0-T MR imaging.
    Tsukamoto K; Matsusue E; Kanasaki Y; Kakite S; Fujii S; Kaminou T; Ogawa T
    Neuroradiology; 2012 Sep; 54(9):947-55. PubMed ID: 22274571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differentiating PSP from MSA using MR planimetric measurements: a systematic review and meta-analysis.
    Heim B; Krismer F; Seppi K
    J Neural Transm (Vienna); 2021 Oct; 128(10):1497-1505. PubMed ID: 34105000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine transporter SPECT imaging in Parkinson's disease and atypical Parkinsonism: a study of 137 patients.
    Constantinides VC; Souvatzoglou M; Paraskevas GP; Chalioti M; Stefanis L; Kapaki E
    Neurol Sci; 2023 May; 44(5):1613-1623. PubMed ID: 36658411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morphometric imaging and quantitative susceptibility mapping as complementary tools in the diagnosis of parkinsonisms.
    Mazzucchi S; Del Prete E; Costagli M; Frosini D; Paoli D; Migaleddu G; Cecchi P; Donatelli G; Morganti R; Siciliano G; Cosottini M; Ceravolo R
    Eur J Neurol; 2022 Oct; 29(10):2944-2955. PubMed ID: 35700041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood neurofilament light chain in Parkinson disease and atypical parkinsonisms: A protocol for systematic review and meta-analysis.
    Wang H; Wang W; Shi H; Han L; Pan P
    Medicine (Baltimore); 2020 Oct; 99(40):e21871. PubMed ID: 33019386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of dystonia between Parkinson's disease and atypical parkinsonism: The clinical usefulness of dystonia distribution and characteristics in the differential diagnosis of parkinsonism.
    Yoon WT
    Neurol Neurochir Pol; 2018; 52(1):48-53. PubMed ID: 29196058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA).
    Katzdobler S; Nübling G; Klietz M; Fietzek UM; Palleis C; Bernhardt AM; Wegner F; Huber M; Rogozinski S; Schneider LS; Spruth EJ; Beyle A; Vogt IR; Brandt M; Hansen N; Glanz W; Brockmann K; Spottke A; Hoffmann DC; Peters O; Priller J; Wiltfang J; Düzel E; Schneider A; Falkenburger B; Klockgether T; Gasser T; Nuscher B; Haass C; Höglinger G; Levin J
    J Neurol; 2024 Oct; 271(10):6991-6999. PubMed ID: 39254698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A follow-up study on brainstem atrophy in progressive supranuclear palsy--when does brain MRI contribute to the differential diagnosis between progressive supranuclear palsy and Parkinson disease?].
    Yamamoto T; Oya Y; Ogawa M; Ogata K; Kawai M
    Rinsho Shinkeigaku; 2003 Jul; 43(7):392-7. PubMed ID: 14582364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging.
    Savoiardo M
    Neurol Sci; 2003 May; 24 Suppl 1():S35-7. PubMed ID: 12774211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Midbrain atrophy in pathologically diagnosed Lewy body disease and clinically diagnosed Parkinson's disease.
    Sako W; Suda A; Taniguchi D; Kamagata K; Shindo A; Ogawa T; Oji Y; Nishikawa N; Hatano T; Aoki S; Hattori N
    J Neurol Sci; 2023 Nov; 454():120821. PubMed ID: 37832378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes.
    Kaiserova M; Chudackova M; Prikrylova Vranova H; Mensikova K; Kastelikova A; Stejskal D; Kanovsky P
    Neurodegener Dis; 2021; 21(1-2):30-35. PubMed ID: 34695830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome.
    Jabbari E; Holland N; Chelban V; Jones PS; Lamb R; Rawlinson C; Guo T; Costantini AA; Tan MMX; Heslegrave AJ; Roncaroli F; Klein JC; Ansorge O; Allinson KSJ; Jaunmuktane Z; Holton JL; Revesz T; Warner TT; Lees AJ; Zetterberg H; Russell LL; Bocchetta M; Rohrer JD; Williams NM; Grosset DG; Burn DJ; Pavese N; Gerhard A; Kobylecki C; Leigh PN; Church A; Hu MTM; Woodside J; Houlden H; Rowe JB; Morris HR
    JAMA Neurol; 2020 Mar; 77(3):377-387. PubMed ID: 31860007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy.
    Compta Y; Giraldo DM; Muñoz E; Antonelli F; Fernández M; Bravo P; Soto M; Cámara A; Torres F; Martí MJ;
    Parkinsonism Relat Disord; 2018 Jan; 46():16-23. PubMed ID: 29107645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Morphometry MRI in the differential diagnosis of parkinsonian syndromes.
    Gama RL; Távora DF; Bomfim RC; Silva CE; Bruin VM; Bruin PF
    Arq Neuropsiquiatr; 2010 Jun; 68(3):333-8. PubMed ID: 20602031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.